Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis

World Journal of Surgical Oncology

Yibing Liu¹  Li Jing¹  Li Feng¹  Zhiguo Zhou¹  Qingju Meng²  Ruoying Deng³  Shuai Shi³  Zhicong Wang³ 

[1] Department of Medical Oncology, Fourth Hospital of Hebei Medical University, 12 JianKang Road, 050011, Shijiazhuang, Hebei Province, China;Department of Oncology, the First Hospital of Xingtai, Xingtai, Hebei Province, China;Department of Orthopedics, the First Hospital, 376 Shunde Road, Qiaodong District, 054001, Xingtai, Hebei Province, China;Hebei Medical University, Shijiazhuang, Hebei Province, China;

关键词: Recombinant human endostatin;    Endostar;    Endostar combined chemotherapy;    Squamous cell lung cancer;    Response rate;    Disease control rate;    Meta-analysis;   

DOI  :  10.1186/s12957-021-02161-1

来源: Springer

【 摘 要 】

BackgroundThis paper aims to compare the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with squamous cell lung cancer (SqCLC).MethodsWe searched the Cochrane Library, PubMed, Embase, CNKI, Wanfang database, Metstr, VIP, and others and manually searched books and magazines until 2019 for articles about the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with SqCLC. A second search was conducted on the review literature. According to the criteria of the literature screen, the relevant randomized controlled trials (RCTs) and nonrandomized controlled trials (non-RCTs) of recombinant human endostatin combined with chemotherapy and chemotherapy alone in the treatment of SqCLC were included. After the data were extracted and analyzed, RevMan 5.3 software was used for meta-analysis for the outcome indicators. Then, heterogeneity tests and sensitivity analyses were carried out, and the publication bias of this study was tested in Stata 13.0 software. Six RCTs and eight non-RCTs were included. In total, 821 patients with SqCLC were included.ResultsThe response rate (RR) was 2.12 (95% CI: 1.57–2.85, p < 0.00001). The disease control rate (DCR) was 2.38 (95% CI: 1.70–3.32, p < 0.00001). The difference between the two groups was statistically significant. Regarding safety, the incidence rates of the adverse reactions cardiotoxicity, leukopenia, thrombocytopenia, and gastrointestinal reactions were not significantly different between the two groups (OR = 1.70, 95% CI: 0.79–3.68; OR = 0.93, 95% CI: 0.61–1.42; OR = 1.08, 95% CI: 0.71–1.64; OR = 0.86, 95% CI: 0.56–1.30, respectively).ConclusionThe combined treatment had a better therapeutic effect than chemotherapy alone. It did not increase the incidence of adverse reactions in the course of treatment.

【 授权许可】

CC BY